Company Overview
Snapshot
Founded in January 2013 by Avi Dascalu, Adastroderm operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of a medical device for early-stage melanoma diagnosis and a healthy aging pharmaceutical drug.
Business overview
Adastroderm is a Health Tech & Life Sciences company focused on dermatology. The company is developing a medical device designed to improve the early diagnosis of malignant melanoma. Additionally, Adastroderm is advancing a healthy aging pharmaceutical drug, which is currently in Phase 2 clinical trials. The company operates within the medical devices and drug discovery and development sectors, targeting healthcare providers and the pharmaceutical industry.
Log in to access full profile ›Company Intelligence Q&A
- What is Adastroderm's primary focus in medical device development?
- Adastroderm is developing a medical device specifically targeted to improve the early stage diagnosis of malignant melanoma.
- What is the status of Adastroderm's pharmaceutical drug development?
- Adastroderm is developing a healthy aging pharmaceutical drug that is currently in Phase 2 clinical trials.
- When was Adastroderm founded and by whom?
- Adastroderm was founded in January 2013 by Avi Dascalu.
- In which sector does Adastroderm primarily operate?
- Adastroderm's primary sector is Health Tech & Life Sciences, with a focus on medical devices and drug discovery and development.
- What is Adastroderm's current funding stage?
- Adastroderm is currently in the Pre-Funding stage, indicating it has not yet secured external investment rounds.